Statins: up to half less cancer in observational studies, no reduction in randomized trials.

Statins and Cancer: Which Statin, Which Cancer, How Much — An Evidence Table

Claude AI - Oct 2026

The lowest cancer mortality and recurrence turn up with lipophilic statins (atorvastatin, simvastatin) in patients who already have liver, pancreatic, breast, prostate and colorectal cancer: observational studies find roughly 15–45% lower risk. But that is not proof the drug causes the benefit. Randomized trials in people without cancer show no effect on cancer incidence or cancer death.[1][2] The only large randomized trial in cancer patients (pravastatin in small-cell lung cancer) was flat.[3][4][5] Bias-controlled analyses shrink or erase much of the observational benefit.[6]

TL;DR

  • Largest and most consistent associations: lipophilic statins and liver cancer (incidence OR 0.51, ≈49% lower);[7] atorvastatin in pancreatic cancer (death HR 0.58, ≈42% lower);[8] simvastatin and breast cancer recurrence (HR 0.70, ≈30% lower);[9][10] statins begun before diagnosis and prostate cancer death (HR 0.55, ≈45% lower);[11] colorectal cancer death (HR ≈0.79–0.82, ≈18–21% lower).[12] All of these come from observational studies.
  • Randomized evidence is null or weak: 27 statin trials (≈175,000 people) found cancer incidence RR 1.00 and cancer mortality RR 1.00.[13][14] LUNGSTAR (pravastatin, n = 846) found HR 1.01. The positive pravastatin trial in liver cancer was small (n = 83)[5] and unblinded.[3][5] When a target-trial emulation removed immortal-time bias, the cancer-specific mortality HR came out at 1.00.[5][6]
  • Bottom line: the evidence is good enough to keep statins going in cancer patients who already take them, and to prefer a lipophilic agent when a statin is indicated anyway. It is not good enough to prescribe statins to treat or prevent cancer outside a trial. Some of the Marik Substack's framing goes beyond its own sources (details below).

Key Findings: Evidence Table

Abbreviations: ACM = all-cause mortality; CSM = cancer-specific mortality; RFS = recurrence-free survival; OS = overall survival; MA = meta-analysis; Pre-dx / Post-dx = statin use before / after diagnosis; NS = not statistically significant.

Statin Cancer Outcome Effect (HR/OR/RR, 95% CI) ≈ % reduction Study type / N Ref
Any statin All cancers CSM, pre-dx use HR 0.85 (0.82–0.87)[5][15][16] ≈15% Danish nationwide cohort / 295,925 patients Marik
Nielsen NEJM 2012
Any statin All cancers ACM, pre-dx use HR 0.85 (0.83–0.87)[15] ≈15% Danish nationwide cohort / 295,925 patients Nielsen NEJM 2012
Any statin All cancers CSM, post-dx use HR 0.77 (0.66–0.88)[5][17] ≈23% MA of 41 observational studies / 990,649 Marik
Zhong 2015
Any statin All cancers ACM, post-dx use HR 0.81 (0.72–0.91)[5][17] ≈19% MA of 41 observational studies / 990,649 Zhong 2015
Any statin All cancers CSM, pre-dx use HR 0.69 (0.60–0.79)[17] ≈31% MA of 41 observational studies / 990,649 Zhong 2015
Any statin Advanced-stage cancers OS / CSS / PFS HR 0.74 (0.67–0.81) / 0.74 (0.61–0.88) / 0.76 (0.65–0.87)[5][18] ≈24–26% MA, 27 studies incl. 3 RCTs / Not reported Marik
Zhou 2023
Any statin Cancers on immune checkpoint inhibitors OS / PFS HR 0.80 (0.71–0.92) / 0.80 (0.69–0.92)[19] ≈20% MA, 25 studies / 46,154 Marik
Liao 2025
Any statin All cancers (people without cancer at entry) Cancer incidence RR 1.00 (0.96–1.05)[1][13] None IPD MA of 27 RCTs / ≈175,000 Marik
CTT 2012
Any statin All cancers (people without cancer at entry) Cancer mortality RR 1.00 (0.93–1.08)[1][13] None IPD MA of 27 RCTs / ≈175,000 CTT 2012
Any statin (new users) Colorectal, breast, prostate, bladder CSM, initiation ≤6 mo after dx HR 1.00 (0.88–1.15)[5][6] None SEER-Medicare target-trial emulation / Not reported Marik
Emilsson 2018
Lipophilic (all) Liver (HCC) Incidence OR 0.51 (0.46–0.57)[20] ≈49% MA, 32 studies / 4,963,518 Meta HCC 2022
Hydrophilic (all) Liver (HCC) Incidence OR 0.77 (0.58–1.02)[20] ≈23% (NS) MA, 32 studies / 4,963,518 Meta HCC 2022
Any statin Liver (HCC) Incidence OR 0.58 (0.51–0.67)[20] ≈42% MA, 32 studies incl. 3 RCTs / 4,963,518 Meta HCC 2022
Lipophilic (simvastatin, atorvastatin) Liver (HCC), viral hepatitis Incidence aHR 0.56 (0.41–0.79)[21] ≈44% Swedish PS-matched cohort / 16,668 Simon 2019
CGH 2022
Lipophilic, ≥600 cDDD Liver (HCC), viral hepatitis Incidence (dose-response) aHR 0.41 (0.32–0.61)[22] ≈59% Swedish PS-matched cohort / 16,668 2 Minute Medicine
Hydrophilic (pravastatin, rosuvastatin) Liver (HCC), viral hepatitis Incidence aHR 0.95 (0.86–1.08)[22] None (NS) Swedish PS-matched cohort / 16,668 2 Minute Medicine
Lipophilic / Hydrophilic Liver (HCC), NAFLD Incidence HR 0.49 (0.37–0.65) / 0.40 (0.21–0.76)[21] ≈51% / ≈60% Cohort / Not reported CGH 2022
Any statin (new users) Liver (HCC) Incidence, cholesterol-adjusted HR 1.16 (0.80–1.69)[23] None (NS) Korean cohort / Not reported Cho 2019
Pravastatin 40 mg Advanced HCC Median survival 18 vs 9 months (P = 0.006)[5][24][25] ≈2× median survival Unblinded RCT / 83 Marik
Kawata 2001
Atorvastatin Pancreatic ACM, pre/post-dx HR 0.58 (0.46–0.72)[5][8] ≈42% US cohort (Kaiser) / 2,142 (149 on atorvastatin) Marik
Huang 2017
Simvastatin Pancreatic ACM, pre/post-dx HR 0.87 (0.77–0.98)[5][8] ≈13% US cohort (Kaiser) / 2,142 Marik
Huang 2017
Any statin Pancreatic ACM HR 0.87 (0.79–0.97)[26] ≈13% US cohort (Kaiser) / 2,142 Huang 2017
Simvastatin / Atorvastatin Pancreatic Cancer death, post-dx HR 0.55 (0.31–0.98) / 0.64 (0.44–0.93)[27] ≈45% / ≈36% Korean cohort / 1,761 (118 statin users) Lee 2016
Simvastatin (moderate–high dose) Pancreatic, resected ACM / recurrence HR 0.56 (0.38–0.83) / 0.61 (0.41–0.89)[28] ≈44% / ≈39% US surgical cohort / Not reported Wu 2015
Any statin Pancreatic CSM, post-dx (time-dependent) HR 0.72 (0.59–0.87)[5][29] ≈28% SEER-Medicare cohort / Not reported Marik
Guo 2025
Any statin Pancreatic (PDAC) ACM, post-dx HR 0.94 (0.89–1.01)[30][31] ≈6% (NS) SEER-Medicare cohort / 7,813 Jeon 2015
Simvastatin (exclusive) Breast, stage I–III Recurrence (10-yr) HR 0.70 (0.57–0.86)[9][10][32] ≈30% (≈10 fewer per 100 women) Danish nationwide cohort / 18,769 Marik
Ahern 2011
Healio
Lipophilic (all) Breast, stage I–III Recurrence HR 0.73 (0.60–0.89)[9] ≈27% Danish nationwide cohort / 18,769 Healio
Hydrophilic (all) Breast, stage I–III Recurrence HR 1.2 (0.79–1.7)[9] None (NS) Danish nationwide cohort / 18,769 Healio
Any statin Breast RFS HR 0.64 (0.53–0.79)[5][33] ≈36% MA, 10 studies / Not reported Marik
Manthravadi 2016
Lipophilic / Hydrophilic Breast RFS HR 0.72 (0.59–0.89) / 0.80 (0.44–1.46)[33][34] ≈28% / ≈20% (NS) MA / Not reported Manthravadi 2016
Any statin Breast Breast cancer death HR 0.70 (0.46–1.06)[35] ≈30% (NS) MA / Not reported BJC 2025
Any statin Breast, HR+ Recurrence / mortality HR 0.77 (0.61–0.98)[34] / 0.77 (0.73–0.81)[34] ≈23% MA, 7 cohorts / 267,913 HR+ MA 2026
Any statin, post-dx (2-yr lag) Breast Breast cancer death HR 0.76 (0.61–0.94)[36] ≈24% New Zealand cohort / Not reported NZ cohort 2023
Any statin, ≥3 years Breast Breast cancer death (duration) HR 0.68 (0.51–0.89)[36] ≈32% New Zealand cohort / Not reported NZ cohort 2023
Any statin, new users Breast Breast cancer death HR 0.91 (0.69–1.19)[36] ≈9% (NS) New Zealand cohort / Not reported NZ cohort 2023
Atorvastatin 80 mg × 2 wk Breast (HMGCR+) Ki-67 proliferation −24% in HMGCR+ tumors (P = 0.02); −7.6% in all tumors (P = 0.39) Not applicable (biomarker) Window-of-opportunity trial (Bjarnadottir 2013) / 50 Marik
Any statin, post-dx Prostate CSM HR 0.76 (0.66–0.88)[37][38] ≈24% UK cohort / 11,772 Marik
Yu 2014
Any statin, pre- and post-dx Prostate CSM HR 0.55 (0.41–0.74)[11][38] ≈45% UK cohort / 11,772 Yu 2014
Any statin, post-dx only Prostate CSM HR 0.82 (0.71–0.96)[38] ≈18% UK cohort / 11,772 Yu 2014
Any statin, post-dx Prostate CSM HR 0.83 (0.77–0.89)[39] ≈17% Danish cohort / 31,790 JCO editorial 2017
Any statin Prostate Diagnosis (vs antihypertensive users) HR 0.69 (0.52–0.90)[40] ≈31% US veterans cohort / 55,875 Marik
Farwell 2011
Any statin Prostate High-grade diagnosis HR 0.40 (0.24–0.65)[40] ≈60% US veterans cohort / 55,875 Farwell 2011
Any statin Prostate Total / advanced incidence RR 0.93 (0.87–0.99) / 0.80 (0.70–0.90)[41][42] ≈7% / ≈20% MA, 27 observational studies / Not reported Bansal 2012
Any statin Prostate Total incidence (RCTs) RR 1.02 (0.90–1.14)[43] None (NS) MA of 6 RCTs + 36 observational / Not reported Sci Rep 2016
Atorvastatin, pravastatin, rosuvastatin Advanced prostate on ADT ACM Not reported Stronger than other statins[44] Taiwanese cohort / 5,749 EJC 2019
Any statin, pre-dx Colorectal CSM HR 0.82 (0.79–0.86)[45] ≈18% MA, 6 studies / 86,622 Marik
Gray 2016
Any statin, post-dx Colorectal CSM HR 0.90 (0.77–1.05)[45] ≈10% (NS) Scottish cohort / Not reported Gray 2016
Any statin, post-dx / pre-dx Colorectal CSM HR 0.79 (0.70–0.89) / 0.82 (0.79–0.86)[12] ≈21% / ≈18% MA, 14 studies / 130,994 Cancer Med 2019
Any statin Colorectal CSM ("convincing" grade) HR 0.82 (0.79–0.85)[46] ≈18% Umbrella review / Not reported Umbrella JCM 2020
Any statin, post-dx Lung CSM (time-dependent) HR 0.81 (0.74–0.88)[5][29] ≈19% SEER-Medicare cohort / Not reported Marik
Guo 2025
Atorvastatin / Simvastatin Lung, squamous CSM HR 0.87 (0.76–0.99) / 0.88 (0.79–0.99)[47] ≈13% / ≈12% Cohort / Not reported Lung subtypes 2018
Pravastatin 40 mg + chemo Small-cell lung OS HR 1.01 (0.88–1.16)[5][48][49] None Double-blind phase III RCT / 846 Marik
LUNGSTAR 2017
Any statin Esophageal Incidence OR 0.65 (0.57–0.75)[50][51] ≈35% MA, 21 studies / Not reported Esophageal MA 2024
Any statin Esophageal Incidence OR 0.72 (0.60–0.86)[52] ≈28% MA / Not reported Singh CGH 2013
Any statin Gastric Incidence RR 0.72 (0.64–0.81)[53] ≈28% MA of observational studies / Not reported JCM 2022
Any statin Gastric Incidence (conservative) OR 0.84 (0.78–0.90)[54] ≈16% MA, 11 studies incl. RCT post-hoc / 5,581 cases Singh Ann Oncol 2013
Any statin Ovarian Incidence RR 0.88 (0.76–1.03)[55] ≈12% (NS) MA, 19 studies / 1,999,362 Liu 2019
Lipophilic, post-dx Ovarian CSM HR 0.92 (0.84–0.99)[56] ≈8% Australian cohort / Not reported Australia 2021
Lipophilic, pre-dx Ovarian CSM HR 1.00 (0.93–1.08)[56] None Australian cohort / Not reported Australia 2021
Any statin Endometrial Incidence RR 0.88 (0.78–1.00)[55] ≈12% (borderline) MA, 19 studies / 1,999,362 Liu 2019
Any statin Endometrial OS / disease-specific survival HR 0.80 (0.66–0.95) / 0.69 (0.61–0.79)[57] ≈20% / ≈31% MA, 7 observational studies / Not reported Endometrial MA 2019
Any statin Kidney (RCC) Incidence HR 0.64 (0.38–0.87)[58] ≈36% Taiwanese cohort / Not reported Chou 2020
Any statin Kidney (RCC) OS / CSS HR 0.81 (0.69–0.96) / 0.72 (0.35–1.50)[59] ≈19% / NS MA / Not reported Urologic MA 2015
Any statin Bladder Incidence RR 1.07 (0.95–1.21)[60][61][62] ≈7% increase (NS) MA, 13 studies / Not reported Zhang 2013
Any statin Bladder Incidence (RCTs) RR 0.89 (0.68–1.16)[63] ≈11% (NS) MA / Not reported Symvoulidis 2023
Any statin Melanoma / skin Incidence No significant association[61][64] None Umbrella MA / Not reported Umbrella AORT 2022
Any statin Hematologic (all) Incidence RR 0.81 (0.70–0.92)[65][66] ≈19% MA incl. RCTs / Not reported Yi 2014
Any statin Leukemia / NHL Incidence RR 0.83 (0.74–0.92) / 0.81 (0.68–0.96)[67] ≈17% / ≈19% MA of observational studies / Not reported Pradelli 2015
Any statin Multiple myeloma Incidence OR 0.80 (0.68–0.93)[68][69] ≈20% MA, 10 studies / ≈19.8 million Myeloma MA 2020
Any statin Glioblastoma OS HR 0.98 (0.87–1.11)[5][70] None (NS) MA, 5 retrospective studies / 2,519 Marik
Xie 2020

Strongest Findings

  • Liver cancer (HCC) with lipophilic statins has the largest and most consistent signal. Across 32 studies and nearly 5 million people, lipophilic statins were tied to ≈49% lower HCC incidence; hydrophilic statins were not significant[7] [Meta HCC 2022]. The Swedish viral-hepatitis cohort showed the same lipophilic-only pattern, with a dose-response down to aHR 0.41 at ≥600 cumulative daily doses[22][71] [Simon 2019]. One caveat: a Korean analysis that adjusted for cholesterol at statin start found the protective association disappeared (HR 1.16)[23] [Cho 2019]. So part of this signal may be confounding by cholesterol level.
  • Atorvastatin and simvastatin in pancreatic cancer are the clearest case where individual statins differ. In the Kaiser cohort, atorvastatin had HR 0.58 and simvastatin 0.87,[5] and no other statin had an independent effect[8] [Huang 2017]. A Korean cohort found the same two drugs mattered[27] [Lee 2016]. The SEER-Medicare time-dependent analysis found HR 0.72[5] [Guo 2025], but an earlier SEER-Medicare study was null overall (HR 0.94)[29][30] [Jeon 2015].
  • Breast cancer recurrence with lipophilic statins (mainly simvastatin) is consistent. In the Danish cohort, simvastatin had HR 0.70,[32] lipophilic statins overall 0.73, and hydrophilic statins showed no benefit[9][10] [Ahern 2011]. A meta-analysis of RFS gave 0.72 for lipophilic statins and a non-significant result for hydrophilic statins[33] [Manthravadi 2016]. Effects on breast cancer death are weaker or borderline.[35]
  • Prostate cancer: statins appear to protect against lethal disease, not cancer in general. The CSM benefit is largest in men who used statins before diagnosis (HR 0.55) and smaller with post-diagnosis use alone (0.82)[11][38] [Yu 2014]. Advanced-disease incidence is ≈20% lower, but total incidence is barely changed and null in RCTs[42][43] [[Bansal 2012](https://pubmed.ncbi.nlm.nih.gov/23049713/)] [Sci Rep 2016].
  • Colorectal CSM is the only pairing an umbrella review graded "convincing" (HR 0.82)[46] [Umbrella JCM 2020]. Even so, post-diagnosis use alone was non-significant in the large Scottish cohort[45] [Gray 2016].
  • Null or no clear benefit: glioblastoma, bladder, melanoma/skin, ovarian incidence, and pravastatin in small-cell lung cancer.[5][48][55][61][70]

How the Marik Article Compares With Its Sources

  • Most figures in the Substack match the primary papers: Nielsen 0.85, Zhong 0.77/0.81, Huang 0.58/0.87, Yu 0.76, Guo 0.72/0.81, Liao 0.80, Emilsson 1.00, Xie 0.98, LUNGSTAR 1.01, and CTT null.[5]
  • Ahern 2011 is misdescribed. The article says lipophilic statins were tied to "a 10% reduction in recurrence."[5] The study actually found ≈10 fewer recurrences per 100 women at 10 years, which is an absolute difference. The relative reduction was ≈30% (HR 0.70)[10][32][72] [Ahern 2011].
  • Farwell 2011's "31% lower risk of prostate cancer diagnosis" compared statin users with men taking antihypertensive drugs, not with the general population[40] [Farwell 2011].
  • "Doubled median survival" in HCC comes from an unblinded trial of 83 patients.[5][24] The LUNGSTAR investigators attributed that result "probably" to "a lack of blinding and small study size"[3] [LUNGSTAR 2017]. It is also notable that the drug was pravastatin, a hydrophilic statin. That sits awkwardly with the article's argument that hydrophilic pravastatin explains LUNGSTAR's failure.[5]
  • The "26% lower mortality in advanced cancers" meta-analysis is mostly observational (27 studies, only 3 RCTs) and very heterogeneous (I² 85.4%)[5][18] [Zhou 2023].

Evidence Quality and Limitations

  • Healthy-user / adherence bias: people who keep taking a preventive drug tend to be healthier and more engaged with care. This makes any drug look protective.
  • Immortal-time bias: classifying patients as "users" if they ever start a statin after diagnosis credits them with survival time before they started. When Emilsson's target-trial emulation corrected for this, cancer-specific mortality was HR 1.00 for new users.[5] A naïve "ever initiated in first 6 months" analysis of the same data produced a spurious HR of 0.62–0.67[6] [Emilsson 2018]. New-user analyses in breast cancer were also null (HR 0.91)[36] [NZ cohort 2023].
  • Confounding by cholesterol and indication: in HCC, the benefit disappeared after adjusting for cholesterol[23] [Cho 2019].
  • Randomized data: in the CTT Collaboration's analysis of 27 trials and ≈175,000 people (Emberson et al., PLoS ONE 2012), "a median of five years of statin therapy had no effect on the incidence of, or mortality from, any type of cancer." There was also no effect at any of 23 individual cancer-site categories or for any individual statin [CTT 2012]. These trials enrolled people without cancer and ran for about 5 years, so they cannot rule out a treatment effect in established cancer.[5][73]
  • Individual-statin data are sparse. Head-to-head numbers exist mainly for atorvastatin and simvastatin. We found no robust cancer-specific estimates for fluvastatin or pitavastatin; for lovastatin, rosuvastatin and pravastatin, most data come from lipophilic/hydrophilic groupings.
  • Heterogeneity: many pooled estimates come with high I² and wide variation between Asian and Western studies.[66][74][75]

Recommendations

  • If you already take a statin and have cancer: keep taking it. No data suggest harm, and the observational signal favors continuing.
  • If a statin is indicated for cardiovascular reasons: choosing atorvastatin or simvastatin is reasonable given the lipophilic-favoring data in HCC, breast and pancreatic cancer. Check CYP3A4 interactions with cancer drugs first.[5]
  • Starting a statin solely as cancer therapy or prevention: this is not supported by RCT evidence. Consider it only within a clinical trial or after shared decision-making with an oncologist.
  • Treat the Substack's ≈15–45% figures as associations, not expected treatment effects.

Sources

Sources

  1. Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo - PMC
  2. Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy
  3. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)
  4. (PDF) Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)
  5. Statins and Cancer: Following the Science Beyond Cholesterol
  6. Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer - PMC
  7. A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma - PMC
  8. Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer
  9. Simvastatin associated with reduced risk for breast cancer recurrence
  10. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study - PubMed
  11. Use of statins and the risk of death in patients with prostate cancer - PubMed
  12. Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta‐analysis
  13. (PDF) Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy
  14. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy - PubMed
  15. Statin Use Associated with Reduced Cancer-related Mortality in Danish Study - The ASCO Post
  16. Reply to Comment on ‘Statin use and all-cancer survival: prospective results from the Women’s Health Initiative’
  17. Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies - PubMed
  18. Background
  19. Concomitant Statin Use and Survival in Patients With Cancer on Immune Checkpoint Inhibitors: A Meta-Analysis - PubMed
  20. A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma
  21. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease - Clinical Gastroenterology and Hepatology
  22. Lipophilic statins associated with reduced risk for hepatocellular carcinoma
  23. Higher cholesterol levels, not statin use, are associated with a lower risk of hepatocellular carcinoma - PubMed
  24. (PDF) Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
  25. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
  26. Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer - PubMed
  27. Statin Use and Its Impact on Survival in Pancreatic Cancer Patients - PubMed
  28. pmc.ncbi.nlm.nih.gov
  29. Statin use after cancer diagnosis and survival among patients with cancer
  30. The Association of Statin Use after Cancer Diagnosis with Survival in Pancreatic Cancer Patients: A SEER-Medicare Analysis
  31. The Association of Statin Use after Cancer Diagnosis with Survival in Pancreatic Cancer Patients: A SEER-Medicare Analysis
  32. Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
  33. Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta‐analysis - Manthravadi - 2016 - International Journal of Cancer - Wiley Online Library
  34. The impact of statin therapy on the prognosis of hormone receptor-positive breast cancer: a systematic review and meta-analysis - PMC
  35. Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics
  36. Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study - PMC
  37. Use of Statins and the Risk of Death in Patients With Prostate Cancer
  38. Statins reduce mortality risk
  39. Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?
  40. Statins and prostate cancer diagnosis and grade in a veterans population - PubMed
  41. Statin use and risk of prostate cancer: a meta-analysis of observational studies - PubMed
  42. Background
  43. LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies
  44. Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy - ScienceDirect
  45. Statin use and survival in colorectal cancer: Results from a population-based cohort study and an updated systematic review and meta-analysis - ScienceDirect
  46. Statin and Cancer Mortality and Survival: An Umbrella Systematic Review and Meta-Analysis
  47. Statins associated with improved mortality among patients with certain histological subtypes of lung cancer - PMC
  48. Do Statins Improve Survival in Small-Cell Lung Cancer?
  49. No Survival Benefit When Pravastatin Is Added to Standard Chemotherapy in Small Cell Lung Cancer - The ASCO Post
  50. A Systematic Review and Meta-analysis of the Relationship between Statin Intake and Esophageal Cancer - PubMed
  51. A Systematic Review and Meta-analysis of the Relationship between Statin Intake and Esophageal Cancer
  52. Statins Are Associated With Reduced Risk of Esophageal Cancer, Particularly in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis - Clinical Gastroenterology and Hepatology
  53. Statins and the Risk of Gastric Cancer: A Systematic Review and Meta-Analysis
  54. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis - ScienceDirect
  55. Statin use and the risk of ovarian and endometrial cancers: a meta-analysis
  56. Statin use and survival among women with ovarian cancer: an Australian national data-linkage study - PMC
  57. The association between statin use and endometrial cancer survival outcome: A meta-analysis - PMC
  58. Statin use and the Risk of Renal Cell Carcinoma: National Cohort Study - Yu-Ching Chou, Chih-Hung Lin, Chih-Shung Wong, Wan-Yun Chou, Jin-Yin Chang, Chien-An Sun, 2020
  59. The Prognostic Effect of Statin Use on Urologic... : Medicine
  60. Statin use and risk of bladder cancer: a meta-analysis
  61. Statin use and risk of cancer : Annals of Oncology Research and Therapy
  62. Assessing the role of statin therapy in bladder cancer: evidence from a Mendelian Randomization study - PMC
  63. The Effect of Statins on the Incidence and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis
  64. Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies
  65. Statin Use Is Associated with Reduced Risk of Haematological Malignancies: Evidence from a Meta-Analysis
  66. Statin Use Is Associated with Reduced Risk of Haematological Malignancies: Evidence from a Meta-Analysis
  67. Statin use and risk of multiple myeloma: An analysis from the Cancer Research Network
  68. Receipt of Statins Is Associated With Lower Risk of Multiple Myeloma: Systematic Review and Meta-analysis - PubMed
  69. Receipt of Statins Is Associated With Lower Risk of Multiple Myeloma: Systematic Review and Meta-analysis - ScienceDirect
  70. Whether statin use improves the survival of patients with glioblastoma?: A meta-analysis - PubMed
  71. Lipophilic statins associated with significantly reduced liver cancer incidence and mortality
  72. Do statins cut breast cancer recurrence?
  73. Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy
  74. Statin use and the risk of multiple myeloma: a PRISMA-compliant meta-analysis
  75. The effects of statins in patients with advanced-stage cancers - a systematic review and meta-analysis - PMC

Related in VitaminDWiki

Created October 2026
URL: http://vitamindwiki.com/pages/statins-up-to-half-less-cancer-in-observational-studies-no-reduction-in-randomized-trials/
Printed October 30, 2026